Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies

Abstract

Background:

Delayed-release dimethyl fumarate (DMF) is an approved oral treatment for relapsing forms of multiple sclerosis (MS). Preclinical studies demonstrated that DMF activated the nuclear factor E2–related factor 2 (Nrf2) pathway. DMF and its primary metabolite monomethyl fumarate (MMF) were also shown to promote cytoprotection of cultured central nervous system (CNS) cells via the Nrf2 pathway.

Objective:

To investigate the activation of Nrf2 pathway following ex vivo stimulation of human peripheral blood mononuclear cells (PBMCs) with DMF or MMF, and in DMF-treated patients from two Phase 3 relapsing MS studies DEFINE and CONFIRM.

Methods:

Transcription of Nrf2 target genes NADPH:quinone oxidoreductase-1 (NQO1) and heme-oxygenase-1 (HO1) was measured using Taqman® assays. RNA samples were isolated from ex vivo–stimulated PBMCs and from whole blood samples of 200 patients each from placebo, twice daily (BID) and three times daily (TID) treatments.

Results:

DMF and MMF induced NQO1 and HO1 gene expression in ex vivo–stimulated PBMCs, DMF being the more potent inducer. Induction of NQO1 occurred at lower DMF concentrations compared to that of HO1. In DMF-treated patients, a statistically significant induction of NQO1 was observed relative to baseline and compared to placebo. No statistical significance was reached for HO1 induction.

Conclusion:

These data provide the first evidence of Nrf2 pathway activation from two large pivotal Phase 3 studies of DMF-treated MS patients.

Keywords

Dimethyl fumarate monomethyl fumarate Nrf2 pathway HO1 NQO1 antioxidant response

Get full access to this article

View all access options for this article.

References

Fox

Bethoux

Goldman

et al . Multiple sclerosis: Advances in understanding, diagnosing, and treating the underlying disease. Clev Clin J Med 2006; 73: 91–102.

Noseworthy

Lucchinetti

Rodriguez

et al . Multiple sclerosis. N Engl J Med 2000; 343: 938–952.

Freedman

. Disease-modifying drugs for multiple sclerosis: Current and future aspects. Expert Opin Pharmacother 2006; 7(Suppl. 1): S1–S9.

Gilgun-Sherki

Melamed

Offen

. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J Neurol 2004; 251: 261–268.

Witherick

Wilkins

Scolding

et al . Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis 2010; 2011: 164608.

Linker

Lee

Ryan

et al . Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134: 678–692.

Scannevin

Chollate

Jung

et al . Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012; 341: 274–284.

Parodi

Rossi

Morando

et al . Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol 2015; 130: 279–295.

Chen

Assmann

Krenz

et al . Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest 2014; 124: 2188–2192.

10.

Tang

Zheng

et al . The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 2008; 375: 562–565.

11.

Alfieri

Srivastava

Siow

et al . Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J Physiol 2011; 589: 4125–4136.

12.

Brennan

Patel

Allaire

et al . Pharmacodynamics of dimethyl fumarate are tissue specific and involve NRF2-dependent and -independent mechanisms. Antioxid Redox Signal 2016; 24: 1058–1071.

13.

Fox

Miller

Phillips

et al . Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.

14.

Gold

Kappos

Arnold

et al . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098–1107.

15.

Brennan

Allaire

Huss

et al . Dimethyl fumarate and monomethyl fumarate are distinguished by non-overlapping pharmacodynamic effects in vivo (Poster presentation, number P1.206). Neurology 2014; 82(2014).

16.

Gold

Linker

Stangel

. Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 2012; 142: 44–48.

17.

Schulze-Topphoff

Varrin-Doyer

Pekarek

et al . Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci USA 2016; 113: 4777–4782.

18.

Dibbert

Clement

Skak-Nielsen

et al . Detection of fumarate-glutathione adducts in the portal vein blood of rats: Evidence for rapid dimethylfumarate metabolism. Arch Dermatol Res 2013; 305: 447–451.

19.

Litjens

Burggraaf

Van Strijen

et al . Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 2004; 58: 429–432.

20.

Werdenberg

Joshi

Wolffram

et al . Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 2003; 24: 259–273.

21.

Edwards

Penner

Rogge

et al . A pharmacokinetic study of delayed-release dimethyl fumarate to evaluate cerebrospinal fluid penetration in patients with secondary progressive multiple sclerosis. ECTRIMS Online Libr 2016; 2016: 145596.

22.

Ghashghaeinia

Bobbala

Wieder

et al . Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling. Am J Physiol Cell Physiol 2010; 299: C791–C804.

23.

Rostami-Yazdi

Clement

Schmidt

et al . Detection of metabolites of fumaric acid esters in human urine: Implications for their mode of action. J Invest Dermatol 2009; 129: 231–234.

24.

Zhang

Gao

et al . Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 2013; 100: 30–47.

25.

Nguyen

Yang

Pickett

. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 2004; 37: 433–441.

26.

Yeligar

Machida

Kalra

. Ethanol-induced HO-1 and NQO1 are differentially regulated by HIF-1alpha and Nrf2 to attenuate inflammatory cytokine expression. J Biol Chem 2010; 285:35359–35373.

27.

Pugazhenthi

Akhov

Selvaraj

et al . Regulation of heme oxygenase-1 expression by demethoxy curcuminoids through Nrf2 by a PI3-kinase/Akt-mediated pathway in mouse beta-cells. Am J Physiol Endocrinol Metab 2007; 293: E645–E655.

28.

Zhang

Ohta

Maruyama

et al . BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol Cell Biol 2006; 26: 7942–7952.

29.

Nioi

McMahon

Itoh

et al . Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: Reassessment of the ARE consensus sequence. Biochem J 2003; 374: 337–348.

30.

Michell-Robinson

Moore

Healy

et al . Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Ann Clin Transl Neurol 2016; 3: 27–41.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB